EURURO Vol. 71 No. 5

E160 844

Corrigendum
Corrigendum re: ‘‘Impact of Prostate-specific [2_TD$DIFF]Antigen (PSA)
Screening Trials and Revised PSA Screening Guidelines on
Rates of Prostate Biopsy and Postbiopsy Complications’’
[Eur Urol 2017;71:55–65]
Boris Gershman Holly K. Van Houten Jeph Herrin Daniel M. Moreira Simon P. Kim
Nilay D. Shah R. Jeffrey Karnes
a Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA; b Mayo Clinic Robert D. and Patricia E. Kern Center for the Science
of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA; cDivision of Cardiology, Yale University School of Medicine, New Haven, CT, USA; d Health Research
and Educational Trust, Chicago, IL, USA; e Department of Urology, University of Illinois, Chicago, IL, USA; f Department of Urology, University Hospitals Case
Medical Center, Case Western Reserve University School of Medicine, Urology Institute, Cleveland, OH, USA; g OptumLabs, Cambridge, MA, USA; h Department
of Urology, Mayo Clinic, Rochester, MN, USA
We wish to report two typographical errors that recently came to our attention in this article.
(1) The correct affiliation for Dr. R. Jeffrey Karnes is ‘‘a Department of Urology, Mayo Clinic, Rochester, MN, USA’’ rather
than ‘‘d Health Research and Educational Trust, Chicago, IL, USA’’.
(2) In the first paragraph of the Discussion, the text ‘‘a concurrent 22% decrease’’ should be ‘‘a concurrent 10% decrease.’’
Similarly, in paragraph 5, the text ‘‘an absolute 22% reduction’’ should be ‘‘an absolute 10% reduction.’’ The remainder of
the article correctly specifies the ‘‘10%’’ reduction in 30-d complication rates, and the findings and conclusions remain
unaltered.
Conflicts of interest: The authors have nothing to disclose.
available at
journal homepage:
DOI of original article: .
* Corresponding author. Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN[1_TD$DIFF] 55905, USA. Tel. +1 507 2669968;
Fax: +1 507 2844951.
E-mail address: (R.J. Karnes).
0302-2838/